The Challenges of New Biologic Therapies in Pediatrics: An Update on the Limited Therapeutic Options for Juvenile Psoriatic Arthritis.

Anna Costello, Pamela Weiss

Abstract readReview

In one paragraph

Review in Rheumatic diseases clinics of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anna CostelloPediatric Rheumatology, Division of Rheumatology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Electronic address: COSTELLOA@chop.edu.

Pamela WeissDivision of Rheumatology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

Funding

Mentoring and Patient Oriented Research in Juvenile SpondyloarthritisK24AR078950 · NIAMS · CHILDREN'S HOSP OF PHILADELPHIA · PI Pamela Fitch Weiss · 2022 to 2026

$664k

NIAMS NIH HHS K24 AR078950

6 · The paper itself

Abstract

Juvenile psoriatic arthritis (JPsA) is a relatively small and clinically heterogenous subtype of juvenile idiopathic arthritis. There is a very limited therapeutic arsenal with few Food and Drug Administration-approved therapies and a lack of published treatment guidelines for JPsA. Pediatric drug development and approvals lag far beyond those in adult medicine as there are numerous barriers to performing studies on and developing medications for rare pediatric diseases like JPsA. There have been regulatory acts over the past several decades designed to enhance the pipeline of pediatric drug development which is a reason for optimism about the future of therapeutic options for JPsA patients.

Indexed as

Antirheumatic AgentsArthritis, JuvenileArthritis, PsoriaticBiological ProductsBiological TherapyChildHumansAntirheumatic AgentsBiological ProductsJuvenile idiopathic arthritisPharmaceutical developmentPsoriatic arthritis

Identifiers

PMID40681282

DOI10.1016/j.rdc.2025.05.002

PMCPMC13058857

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.